Sanovel Targets Global Pharma Leadership with Domestic Manufacturing Power

Sanovel, a stalwart of Turkey's pharmaceutical industry, is signaling a transformation from a domestic manufacturer to a global health giant, driven by a partnership structure attracting international investors and a robust export-oriented strategy. With a 43-year history rooted in science and quality, the company has evolved into a reliable solution partner for over 50 countries across five continents under the leadership of CEO Hülya Yalın.

Domestic Capital Structure Reflecting Global Confidence

The inclusion of international investors in the company's shareholding is viewed not merely as a corporate success but as a testament to the global confidence in Turkey's production capacity. Adhering to a 100% local production principle, Sanovel positions the reduction of external dependency as a national mission.

■Managed from a Turkey-centered production campus with a workforce of 2,000 people.

■Holds a vast portfolio with over 400 licensed drugs and 60 brands.

■Operates in critical treatment areas including pain, inflammation, cardiovascular, and neurology.

Fourfold Export Surge and Capacity Expansion

Sanovel has solidified its financial standing with significant growth momentum over the last five years, investing in production infrastructure to guarantee sustainability. Growing 10.5-fold in value according to IQVIA data, the company ranks among the leading players, particularly in diabetes and cardiology markets.

■Export volume increased 4-fold in the last 5 years, boosting foreign currency inflows.

■Production capacity expanded from 60 million to 91.5 million boxes.

■Infrastructure strengthened with a $26 million investment in the factory.

■Certified with international quality standards via US FDA and EMA approvals.

Oncology-Focused 2035 Vision and Strategic Milestones

Pivoting towards high-value-added products for the next decade, Sanovel aims to produce oncology drugs—largely imported—in Turkey, thereby contributing to a reduction in the current account deficit and a sustainable healthcare system. The 2035 vision encompasses not just market share expansion but also sustaining competitive advantage through innovation.

■Project teams focusing on oncology aim to reduce import dependency.

■Targets entering the top 10 companies in the Turkish pharma market in the medium term.

■An R&D team of 80 scientists develops next-gen production technologies.

■Reduced carbon footprint by 14.3% and water footprint by 13.9% in 2025.

Such high-value production and export increases are of critical importance for macroeconomic balances. Sanovel’s provision of import substitution, particularly in oncology drugs where currency outflow is high, holds the potential to alleviate pressure on Turkey's current account deficit. The company's $26 million capacity expansion and 4-fold export performance serve as a concrete example of a sustainable growth model, demonstrating how a Turkish brand, trusted by international capital, solidifies its position in the global supply chain.